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Specialty Update
What’s New in Spine Surgery
Keith H. Bridwell, MD, Paul A. Anderson, MD, Scott D. Boden, MD, Alexander R. Vaccaro, MD, PhD, and Jeffrey C. Wang, MD
What’s New in the Treatment of the Cervical Spine
The treatment of cervical myelopathy continues to be debated,
with more data suggesting that mildly symptomatic or
asymptomatic patients can be observed and that, if surgery is
performed, both anterior and posterior approaches have sim-
ilar outcomes. Similarly, the results of a large prospective study
analyzing the outcomes for geriatric patients with odontoid
fractures may provide insight into the best treatment, either
nonoperative or operative. Positive movement in the regulatory
status of posterior cervical fixation has occurred, and a better
understanding of a simple method to prevent surgical site
infection has emerged.
Cervical Myelopathy
Two surgical approaches are commonly used for the treatment
of cervical spondylotic myelopathy: (1) anterior decom-
pression and arthrodesis and (2) laminoplasty. In most cases,
the former directly decompresses the offending ventral ab-
normality, but it can be associated with the complications of
dysphagia, graft extrusions, and complex cerebral spinal fluid
leaks. Laminoplasty is more extensile, but, in general, re-
quires a neutral or lordotic spine in the sagittal plane and is
associated with a higher rate of C5 nerve root palsy. Recently,
multiple clinical trials have demonstrated that both treat-
ments have resulted in substantial functional, neurologic,
and quality-of-life improvements, but no differences have
been found between the two treatments. Reoperation rates
have been greater following anterior treatment.
Odontoid Fractures
Geriatric odontoid fractures are difficult to treat, having sub-
stantial morbidity and a one-year mortality rate of >20%. In
a multicenter study, 159 patients were followed for twelve
months. Treatment decisions were based on shared decision-
making between surgeons and patients. One-third of patients
were managed conservatively. The two groups were similar in
terms of age, demographic characteristics, and baseline medical
status. The overall mortality rate was 18.1%, with a rate of
25.9% in the conservative treatment group and 13.9% in the
surgical treatment group. Statistical analysis that controlled
for confounding variables showed that conservative treat-
ment, older age, and more comorbidities were associated with
higher mortality rates. In the nonoperative treatment group,
seventeen of fifty-nine patients had development of non-
union, of whom thirteen required later C1-C2 arthrodesis.
In this nonoperative treatment group, clinical outcomes were
similar regardless of whether healing occurred or not. No
patient who was managed nonoperatively had neurologic
deterioration.
Lateral Mass Fixation
Posterior cervical screw fixation is widely used and is consid-
ered standard care. The regulatory status of these devices is
problematic as they are currently unclassified and their use is
considered off-label. This has several negative consequences.
Training at hands-on courses in their proper use is prohibited,
and therefore training usually only occurs in the operating
room. Other negative effects are that payment for procedures
involving ‘‘non-approved devices’’ may be denied, research
and development is stifled, and medicolegal and informed
consents are complicated. In September 2012, the U.S. Food
and Drug Administration (FDA) was petitioned to classify
these devices to a Class-2 status. Independent systematic re-
views were performed by the FDA and the Cervical Spine
Research Society. In both cases, a fusion rate of >98% was
found and low complication rates were noted. Currently, the
FDA is preparing a proposed rule to change the classification
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to Class 2, meaning that the screws will be approved for their
intended purpose.
Surgical Site Infection
Prevention of surgical site infection is an essential compo-
nent of patient safety. With use of a large database, the rates of
surgical site infection after various cervical spine surgical
procedures were determined. The prevalence of surgical site
infection was 0.45% for anterior cervical discectomy and
arthrodesis, 0.97% for posterior decompression, and 1.82%
for posterior spinal arthrodesis. Surgical site infections re-
sulted in a fourfold increase in mortality, a fifteen-day longer
duration of hospitalization, and a mean increased cost of
$32,000. One method that has been proposed to prevent
surgical site infection is the placement of vancomycin powder
into the wound at the time of closure. In an animal study,
spinal wounds containing instrumentation were inoculated
with Staphylococcus aureus. The placement of vancomycin
powder into the wound eliminated infection in all animals,
whereas all control animals had positive wound cultures. No
cytotoxic effects were observed in association with vanco-
mycin. In a clinical cohort study, patients undergoing pos-
terior decompression and arthrodesis for the treatment of
myelopathy who were managed with vancomycin powder
were compared with historical controls. The rate of surgical
site infection was reduced from 15% to none. Systemic dis-
tribution of vancomycin and adverse events were not seen.
These findings are consistent with those of other reports
documenting reduction of the rate of surgical site infection
with use of vancomycin powder. The risks to the local tissue
in association with the use of vancomycin powder appear
to be minimal, although the likelihood of development of
resistant organisms over time with long-term use is unknown.
What’s New in Biologic Topics Related to the Spine
The trend toward decreased use of second-site iliac crest
bone graft harvest and increased use of bone graft substitutes
continued in 2012.
Recombinant Osteoinductive Proteins
In 2012, there was a continued focus around potential local
adverse events associated with recombinant human bone
morphogenetic protein-2 (rhBMP-2). In June 2011, a series
of articles, editorials, press releases, and letters to the editor
highlighted major safety risks potentially associated with
rhBMP-2. In June 2011, publications suggested three main
concerns: (1) that rhBMP-2 increased the rate of retrograde
ejaculation in patients managed with anterior lumbar inter-
body arthrodesis (the approved indication), (2) that rhBMP-2
resulted in increased rates of radiculitis, infections, and se-
romas, and (3) that rhBMP-2 was associated with a higher
incidence of cancer. Subsequent studies suggested that many
of the potential side effects seem to be approach-specific, if
not approach-related.
Whether rhBMP-2 increases the rate of retrograde
ejaculation remains unclear. A ten-year cohort controlled
study from the Stanford University experience demonstrated
a twofold increase in retrograde ejaculation in the rhBMP-2
cohort, similar to the findings of the original rhBMP-2 FDA
clinical trial. Another study, from Denver, compared pa-
tients undergoing total disc replacement with those under-
going anterior interbody arthrodesis with rhBMP-2 and
showed no difference in the incidence of retrograde ejacu-
lation related to rhBMP-2. An alternative explanation is
related to surgical exposure (transperitoneal versus retro-
peritoneal) and technique, suggesting that rhBMP-2 was not
responsible for higher rates of retrograde ejaculation. There
has been further clouding of this issue related to the lack
of an exact definition of retrograde ejaculation and how it
is measured.
The issue of radiculitis, presumably due to neuro-
inflammation as reported in some basic science studies,
initially was raised on the basis of reanalysis of relatively small
clinical trials. Most recent analyses have suggested that there
is not an increased incidence of transient radiculitis following
posterolateral use of rhBMP-2.
A recent review of nearly 1400 patients who were man-
aged over seven years showed that seroma formation was
slightly higher among patients managed with rhBMP (3.2%) as
compared with demineralized bone matrix (2.0%) and auto-
graft (1.4%), but these differences were not significant. The
same study showed an overall infection rate of 3.1%, with no
differences due to BMP. These data support the 55,000-patient
Scoliosis Research Society (SRS) study and the 16,000-patient
Medicare database study that showed no increases in the in-
cidences of infection, hematoma/seroma, or overall compli-
cations due to BMP. These studies did show higher hospital
charges, but fewer patients were discharged to skilled nursing
facilities.
Perhaps the most concerning issue that has been raised
is the potential association of rhBMP-2 with cancer. The ap-
proved formulation of 6 to 12 mg delivered on an absorbable
collagen sponge is not associated with any increased risk of
cancer according to the manufacturer’s analysis and there is no
FDA warning, although an external analysis of a relatively small
data set led to a different conclusion. A review of 93,000 pa-
tients in the Medicare database who had undergone lumbar
arthrodesis showed no increased risk of pancreatic cancer. In
late 2012, the Wisconsin group presented a study of 467,000
Medicare patients and found a 6.2% decreased (not increased)
risk of cancer associated with the use of BMP at the time of
spinal arthrodesis.
Work continues on more efficient delivery strategies
for BMPs that presumably will avoid the large early burst phase
of release off current carriers. The early release, while impor-
tant to initiate the healing cascade, if too great, can result in
excessive vascular permeability, leading to many of the local
side effects discussed above.
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Other Bone Graft Substitutes
Although much focus remains on rhBMPs, their relatively
high cost has continued to encourage research involving
other bone graft solutions. Another animal study showed
that platelet-rich plasma, with or without bone marrow, does
not promote posterolateral spine fusion. Silicate-substituted
calcium phosphate, various bone marrow/ceramic combi-
nations, and bioglass continue to be studied for spine fusion
bone graft extenders. Most studies have suggested that these
approaches, including mesenchymal stem cells, still do
not reach the osteoinductive potency of rhBMPs.
Biologic Treatments for Disc Degeneration
Progress toward biologic treatments to prevent or retard disc
degeneration or to heal anular defects continues at a slow pace.
Most studies in the past year have been in vitro proof-of-concept
studies, which are difficult to translate into the in vivo
setting.
What’s New in Spinal Deformity Surgery
There were 129 papers presented from the podium at the
recent SRS annual meeting, held from September 5 to 8,
2012, in Chicago, Illinois.
Idiopathic Scoliosis
There remains considerable interest in selective thoracic ar-
throdesis for the treatment of false double-major curve pat-
terns, in which the thoracic curve is bigger than the lumbar
curve but the lumbar curve is quite structural with substantial
rotation and apical deviation. Several presentations at the re-
cent SRS annual meeting in Chicago addressed this point.
The only conclusions that could be made were that there was
substantial variability among surgeons with regard to the de-
cision to perform a selective thoracic arthrodesis and quite a bit
of variability in terms of the outcome. It was very difficult to
predict outcome on the basis of ‘‘rules.’’ At least one paper
strongly suggested that surgical treatment of adolescent idio-
pathic scoliosis is cost-effective, with a cost of $8182 per
quality-adjusted life-year (QALY), which compares favorably
with coronary artery bypass surgery and total knee arthroplasty.
One interesting study compared pedicle screw con-
structs with hybrid constructs and investigated whether pa-
tients managed with mostly pedicle screw constructs had
fewer returns to the operating room. Patients managed with
pedicle screw constructs had decreased rates of return to
the operating room as compared with those managed with
hybrid constructs (3.5% versus 12.6%).
Adult Spinal Deformity
There is quite a bit of work currently being done to assess
the cost-effectiveness of adult spinal deformity surgery. Most
studies have demonstrated that this group of patients has
significantly improved outcomes at two years of follow-up.
However, the prevalence of neurologic deficit is quite high, as
is prevalence of both proximal junctional kyphosis and cata-
strophic failure at the proximal junction. At least one study
demonstrated that adult spinal deformity impacts physical
function to a similar degree as diabetes and heart disease.
With long fusions to the sacrum, it is mandatory to
protect sacral screws with iliac fixation. Whether it is better
to employ iliac fixation or what is considered S2 alar iliac fix-
ation is not clear. The S2 alar iliac fixation technique has been
compared with first-generation iliac screws and appears to be
advantageous from the standpoint of less prominence posteri-
orly. Current iliac fixation techniques utilize third-generation,
smaller iliac screws and more effective burial of the implants.
With both techniques, the morbidity associated with either
iliac or S2 alar iliac fixation seems to be small, and both
techniques seem to be very effective for protecting sacral
screws.
Three-column osteotomies are becoming increasingly
popular for the treatment of severe deformity in adults. These
procedures are associated with a substantially higher compli-
cation rate in adults than in children.
Neuromuscular Deformities
Surgical treatment in patients with cerebral palsy is associated
with a very substantial wound infection rate (approximately
6.5%). Factors that increase risk of wound infection include the
presence of a gastrostomy tube, large preoperative kyphosis,
longer operative time, and increased age. The ability to walk
and the presence of antibiotics in the bone graft are associated
with a lower rate of infection. One important study compared
life expectancy after surgical versus nonsurgical treatment of
flaccid neuromuscular scoliosis (Duchenne muscular dystro-
phy, spinal muscular atrophy, etc.). The study demonstrated
that life expectancy was higher in the group managed with
surgery than in the group managed without surgery.
Complications
Various strategies have been investigated in an effort to re-
duce the likelihood of deep wound infection following the
reconstruction of a substantial spinal deformity. Most studies
have suggested that intravenous administration of vanco-
mycin as well as a cephalosporin is advantageous. Also,
preoperative skin preparations are more popular now and the
utilization of deep local antibiotics, especially vancomycin,
seems to be beneficial.
Early-Onset Scoliosis
The concept of using instrumentation without arthrodesis
for the treatment of spinal deformity in a pediatric patient
with a progressive deformity that is not controllable with
bracing or casting continues to be popular. The populations
to which this concept most commonly applies are patients
with congenital scoliosis and patients with juvenile or in-
fantile scoliosis under the age of ten years in whom the tri-
radiate cartilages are still open. There are many strategies,
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but no one approach is ideal. One option is to surgically
lengthen the implants and the spine approximately every six
months. Other concepts being investigated are various forms
of segmental self-growing rods with gliding connections
between fixation points and rods as well as magnet-driven
growth rods. Most, if not all, of the growing spine techniques
are not cleared by the FDA, and their use is considered
‘‘off-label.’’
What’s New in the Treatment of Spinal Cord Injury
Injuries to the spinal cord have a devastating impact on pa-
tients. Strategies to optimize neurologic outcome after spinal
cord injury continue to be a focus for clinical and translational
research.
Timing of Surgical Intervention
The Surgical Treatment of Acute Spinal Cord Injury Study
(STASCIS), a multicenter international prospective cohort
study comparing change in American Spinal Injury Associ-
ation (ASIA) Impairment Scale (AIS) following early or late
surgical decompression for the treatment of cervical spinal
cord injury, was recently completed. Early decompression
was defined as that performed less than twenty-four hours
after the injury, and late decompression was defined as that
performed more than twenty-four hours after the injury.
One hundred and thirty-one patients underwent early sur-
gery at a mean of 14.2 hours after the injury, and ninety-one
patients underwent late surgery at a mean of 48.3 hours.
The groups were significantly different, with the early surgery
group having a higher percentage of AIS grade-A and B pa-
tients and a higher rate of treatment with methylpredniso-
lone. In multivariate analysis, adjusting for corticosteroid
administration and injury severity (complete versus incom-
plete), there was no difference between the groups with re-
spect to the odds of improving one AIS grade; however, there
was a 2.8-fold increase in the odds of improving two AIS
grades in favor of early surgical intervention. There were
no differences between the groups in terms of the rates of
complications or mortality. In subgroup analysis, patients
who underwent early decompression and received methyl-
prednisolone had the greatest neurologic improvement.
Corticosteroids also improved outcomes regardless of the
timing of surgical intervention. A major concern associated
with methylprednisolone administration is the development
of complications. However, based on the STASCIS data, a
clinical prediction model of acute inpatient complications
showed that not receiving methylprednisolone was correlated
with a higher rate of complications.
Translational Research
There have been numerous recent advancements in our un-
derstanding of the signaling pathways associated with spinal
cord injury and the regenerative potential of the spinal cord.
The translational gap between animal models and clinical
practice is daunting, but several studies are attempting to
narrow this divide.
Although it was originally developed as an antibiotic
more than thirty years ago, minocycline has demonstrated a
consistent record as a neuroprotective agent in multiple human
and animal models. A phase-I randomized clinical trial of the
effects of high-dose minocycline on human spinal cord injury
was recently completed. In this study, direct cerebrospinal fluid
pressure monitoring with lumbar drains and early surgical
decompression (performed less than twenty-four hours after
the injury) were used in both groups. Very few side effects were
attributed to the study agent. There were no differences between
the groups among patients with thoracic spinal cord injury.
Patients with cervical spinal cord injury who were managed with
minocycline demonstrated a mean improvement of 14 points
on ASIA motor scores in comparison with controls (p = 0.05).
Patients with incomplete cervical injuries showed even greater
improvement, although the difference was not significant. Al-
though minocycline is promising, additional studies are needed
to demonstrate its efficacy for the treatment of spinal cord injury.
Riluzole, a sodium channel blocker, potentially decreases
neuronal injury after spinal cord injury by reducing cytotox-
icity related to increasing calcium concentration and presyn-
aptic release of glutamate. It has been approved by the FDA as
a therapy for amyotrophic lateral sclerosis. A phase-I/II clinical
trial completed enrollment in 2011. Although not published,
the results are promising enough that a phase-III clinical trial
is approved to start in 2013 (clinicaltrials.gov identifier
NCT01597518).
Cellular-based therapies represent another target of
translational research in multiple ongoing studies. A phase-I
trial of intramedullary spinal cord transplantation of purified
human neuronal stem cells in patients with complete (ASIA A)
chronic thoracic spinal cord injury by StemCells (Newark,
California) is currently enrolling patients in Switzerland. As
the transplanted cells are not autologous, a period of immu-
nosuppression is required. Preclinical data suggest that the
transplanted cells localize to the area of injury, where they
differentiate into perineural cell lines, particularly oligoden-
drocytes, which can repair damaged myelin sheath and po-
tentially can promote neural regeneration. TotipotentRX (Los
Angeles, California/New Delhi, India) is currently enrolling
patients for a phase-I/II study in India investigating the use
of autogenous transplantation of hematopoietic-derived stem
cells for the treatment of chronic spinal cord injury. The Miami
Project to Cure Paralysis recently received FDA approval to begin
a phase-I trial of autologous Schwann cell transplantation in
humans with acute and chronic spinal cord injury. The study
protocol requires biopsy of a sensory nerve, from which the
Schwann cells are isolated and cultured prior to replantation.
What’s New in the Treatment of the Lumbar Spine
Pathologies leading to lumbar spinal disorders continue to
be one of the most challenging clinical problems.
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Outcomes of Lumbar Spine Surgery
Outcomes following lumbar spine surgery are of high interest
in this era of cost-effectiveness and utility of spinal surgery.
One study examined the perioperative outcomes, complica-
tions, and costs associated with lumbar spinal arthrodesis in
older patients with spinal stenosis and spondylolisthesis. The
authors examined the United States Medicare claims database
retrospectively. A final cohort of 1672 patients who had been
managed with spinal arthrodesis was included. Fifty percent
of the patients had spinal stenosis only, 10% had spondylolis-
thesis only, and 40% had both. The average age was seventy-
one years, and the average length of hospital stay was 4.6
days. Forty-two percent of the patients had routine discharge,
whereas the majority of patients (55%) were discharged to
an outside facility. One in four patients underwent a reopera-
tion on the lumbar spine within two years, and nearly half
of the patients were readmitted because of a surgery-related
complication. The authors highlighted the areas where im-
provements could be made in the effective delivery and costs of
surgery for patients in this age group and with these diagnoses.
Other authors performed a comparative effectiveness and
cost-utility analysis in which transforaminal lumbar interbody
arthrodesis was compared with the medical treatment of lumbar
spondylolisthesis. This was a prospective, longitudinal, obser-
vational cohort study of eighty patients at a single institution.
The surgical treatment cohort had significant (p < 0.001) im-
provement in all outcome measures at two years, whereas com-
prehensive medical treatment failed to provide significant
improvement. The two-year gain in QALYs was significantly
greater after surgery than after medical treatment (mean, 0.43
compared with 0.06 QALY gained). The total two-year cost was
significantly greater for surgical treatment. The authors con-
cluded that lumbar arthrodesis, when compared with medical
treatment, was cost effective and provided greater two-year
improvement in terms of pain, disability, and quality of life.
Spinal Trauma
There have been several recent studies on traumatic injuries
to the spine. One study compared the long-term results of
operative and nonoperative treatment of thoracolumbar frac-
tures in patients without neurological deficits. In this pro-
spective, randomized, multi-institutional study, forty-seven
consecutive patients with stable burst fractures were separated
into two groups that received either operative or nonoperative
treatment. After an average duration of follow-up of seventeen
years (range, fifteen to twenty years), nineteen patients in the
operative treatment group and twenty-three patients in the
nonoperative treatment group were available for evaluation.
The groups were not significantly different in terms of kyphosis
(average, 14 for the operative treatment group and 16.5 for the
nonoperative treatment group) or pain (average pain score, 4
for the operative treatment group and 2.25 for the nonoperative
treatment group). The Oswestry Disability Index (average, 17.1
for the operative treatment group and 5.5 for the nonoperative
treatment group) and the Roland Morris score (average, 8 for
the operative treatment group and 2 for the nonoperative treat-
ment group) were significantly better in the nonoperative treat-
ment group. All of the Short Form-36 (SF-36) scores favored
the nonoperative treatment group, although only the physical,
social, and general health scores reached significance. Thirty
percent of the individuals in the operative treatment group
showed significant segmental degeneration immediately
caudad to the fusion. One of these individuals had surgery for
the treatment of a problem at an adjacent level, and two of
the patients in the nonoperative treatment group had lami-
nectomies for the treatment of caudad level herniated discs.
More patients who had been managed nonoperatively were
working, and more of the patients in the operative treatment
group were using narcotic pain medications. The authors
concluded that the patients who had been managed non-
operatively reported less pain and had better function than
those who had been managed operatively.
Demographic Characteristics and Spinal Trauma
One group of authors presented a study that evaluated the effects of
demographic characteristics, injury-specific factors, race/ethnicity,
and insurance status on outcomes after spinal trauma with use
data from the National Sample Program of the National Trauma
Data Bank. The study involved a sample of 75,351 incidents of
spine trauma in patients with an average age of 45.8 years. In-
creased age, male sex, Injury Severity Score, and blood pressure
were significant predictors of mortality, whereas age, male sex,
other mechanisms of injury, Injury Severity Score, and blood
pressure influenced complications. Non-white and black/
African-American race increased the risk of mortality. Lack of
insurance was associated with an increased risk of mortality and
with decreases in the number of days of hospitalization, the
number of days in the intensive care unit, and ventilator time.
Appendix: Evidence-Based Orthopaedics
The editorial staff of The Journal reviewed a large number of
recently published research studies related to the musculo-
skeletal system that received a Level of Evidence grade of I or II.
Over 100 medical journals were reviewed to identify these ar-
ticles, which all have high-quality study design. In addition
to articles published previously in this journal or cited already
in the Update, fourteen additional Level-I and II studies were
identified that were relevant to spine surgery. A list of those
titles is available with the online version of this article as a data
supplement at jbjs.org. We have provided a brief commentary
about each of the articles to help to guide your further reading,
in an evidence-based fashion, in this subspecialty area.
Upcoming Meetings and Events Related to Spine
Surgery
 The Scoliosis Research Society (SRS) Forty-seventh
Annual meeting will be held on September 18 through
23, 2013, in Lyon, France. Web site: www.srs.org
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 The EuroSpine annual meeting will be held on
October 2 through 4, 2013, in Liverpool, United
Kingdom. Web site: www.eurospine.org
 The North American Spine Society (NASS) Twenty-
seventh Annual Meeting will be held on October 9
through 12, 2013, in New Orleans, Louisiana. Web site:
www.spine.org
 The Cervical Spine Research Society (CSRS) Forty-first
Annual Meeting will be held on December 5 through 7,
2013, at the Century Plaza Hyatt Regency in Los
Angeles, California. Web site: www.csrs.org
 The AANS/CNS (American Association of Neuro-
logical Surgeons/Congress of Neurological Sur-
geons) Section on Disorders of the Spine and
Peripheral Nerves Annual Meeting will be held on
March 5 through March 8, 2014, at Walt Disney
World Swan and Dolphin Resort in Orlando, Florida.
Web site: http://spinesection.org
 The Federation of Spine Associations will present
the spine program at Specialty Day at the Annual
Meeting of the American Academy of Orthopaedic
Surgeons (AAOS) on March 14, 2014, in New
Orleans, Louisiana. Web site: www.aaos.org
 The International Society for the Advancement of
Spine Surgery (ISASS) Fourteenth Annual Meeting
will be held on April 29 through May 2, 2014,
in Miami, Florida. Web site: www.isass.org
 The American Spinal Injury Association (ASIA) Forty-
first Annual Meeting will be held on May 14 through
16, 2014, in San Antonio, Texas, with a precourse on
May 13, 2014. Web site: www.asia-spinalinjury.org
 The International Society for the Study of the Lumbar
Spine (ISSLS) annual meeting will be held on June 3
through 7, 2014 in Seoul, Korea. Web site: www.issls.org
 The International Meeting on Advanced Spine Tech-
niques (IMAST) Twenty-first Annual Meeting will be
held on July 16 through 19, 2014, in Valencia, Spain.
Web site: http://www.srs.org/meetings/future_meetings.
htm
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